抗体诱导的重症肌无力中乙酰胆碱受体降解：临床关联及发病机制意义

Antibody-induced degradation of acetylcholine receptor in myasthenia gravis: clinical correlates and pathogenetic significance.

作者信息

Tronconi B C, Brigonzi A, Fumagalli G, Sher M, Cosi V, Piccolo G, Clementi F

出版信息

Neurology. 1981 Nov;31(11):1440-4. doi: 10.1212/wnl.31.11.1440.

DOI:10.1212/wnl.31.11.1440

PMID:7198191

Abstract

Sera of myasthenic patients containing anti-AChR antibodies increase the rate of degradation of mammalian AChR. This phenomenon, antigenic modulation (AMd), was tested on AChR of rat myotubes in serum from 48 myasthenic patients. Sixty-six percent of the sera increased AChR degradation. AMd activity was higher in more severely affected patients, paralleled clinical evolution in individual patients, and was related to AChR-antibody titer. Steroid treatment and thymectomy did not affect AMd activity. Patients who had a thymoma always had greater AMd activity.

摘要

含有抗乙酰胆碱受体（AChR）抗体的重症肌无力患者血清会提高哺乳动物AChR的降解速率。这种现象，即抗原调变（AMd），在48例重症肌无力患者血清中的大鼠肌管AChR上进行了测试。66%的血清增加了AChR降解。AMd活性在病情更严重的患者中更高，与个体患者的临床病程平行，并且与AChR抗体滴度相关。类固醇治疗和胸腺切除术不影响AMd活性。患有胸腺瘤的患者AMd活性总是更高。